Research programme: immuno-oncology targeted antibodies - Checkpoint Therapeutics

Drug Profile

Research programme: immuno-oncology targeted antibodies - Checkpoint Therapeutics

Alternative Names: Anti-CAIX antibodies; Anti-GITR antibodies; Anti-PD-L1 antibodies; CK 301; CK 302

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Checkpoint Therapeutics; TG Therapeutics Inc
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Carbonic anhydrase inhibitors; CD274 antigen inhibitors; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 02 May 2017 Checkpoint Therapeutics has patents pending for anti-PD-1 antibodies in Australia, Canada, Europe, Israel, South Korea and USA
  • 28 Apr 2017 Checkpoint Therapeutics announces intention to submit an IND application for CK 301 for Cancer in 2017
  • 28 Apr 2017 Checkpoint Therapeutics announces intention to submit an IND application for the anti-GITR antibody CK 302 and anti-CAIX antibody for Cancer in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top